866-997-4948(US-Canada Toll Free)

Hairy Cell Leukemia - Pipeline Review, H1 2014

Published By :

Global Markets Direct

Published Date : Apr 2014

Category :

Oncology

No. of Pages : 70 Pages

Hairy Cell Leukemia Pipeline Review, H1 2014, provides an overview of the Hairy Cell Leukemias therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hairy Cell Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hairy Cell Leukemia and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Hairy Cell Leukemia
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
  • The report reviews key players involved in the therapeutics development for Hairy Cell Leukemia and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects 
  • A review of the Hairy Cell Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Hairy Cell Leukemia pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Hairy Cell Leukemia
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Hairy Cell Leukemia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Content

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Hairy Cell Leukemia Overview 7
Therapeutics Development 8
Pipeline Products for Hairy Cell Leukemia - Overview 8
Pipeline Products for Hairy Cell Leukemia - Comparative Analysis 9
Hairy Cell Leukemia - Therapeutics under Development by Companies 10
Hairy Cell Leukemia - Therapeutics under Investigation by Universities/Institutes 12
Hairy Cell Leukemia - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Unknown Stage Products 16
Hairy Cell Leukemia - Products under Development by Companies 17
Hairy Cell Leukemia - Products under Investigation by Universities/Institutes 18
Hairy Cell Leukemia - Companies Involved in Therapeutics Development 19
MedImmune, LLC 19
Plexxikon Inc. 20
Incyte Corporation 21
Mundipharma International Limited 22
Stemline Therapeutics, Inc. 23
Onconova Therapeutics, Inc. 24
Inbiopro Solutions Pvt. Ltd. 25
Hairy Cell Leukemia - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
moxetumomab pasudotox - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
forodesine hydrochloride - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Anti-Tac(Fv)-PE38 Immunotoxin - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
SL-401 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
rigosertib sodium - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
INCB-040093 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
PLX-8394 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
IBPB-006-IA - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
interferon alfa-2a biosimilar - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
interferon alfa-2b biosimilar - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
blinatumomab - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Hairy Cell Leukemia - Recent Pipeline Updates 54
Hairy Cell Leukemia - Discontinued Products 67
Hairy Cell Leukemia - Product Development Milestones 68
Featured News & Press Releases 68
May 16, 2013: AstraZeneca\'s MedImmune Enrolls First Patient In Phase III Leukemia Trial Of Moxetumomab Pasudotox 68

Appendix 69
Methodology 69
Coverage 69
Secondary Research 69
Primary Research 69
Expert Panel Validation 69
Contact Us 70
Disclaimer 70

List of Table


Number of Products under Development for Hairy Cell Leukemia, H1 2014 8
Number of Products under Development for Hairy Cell Leukemia - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 11
Number of Products under Investigation by Universities/Institutes, H1 2014 12
Comparative Analysis by Late Stage Development, H1 2014 13
Comparative Analysis by Clinical Stage Development, H1 2014 14
Comparative Analysis by Early Stage Development, H1 2014 15
Comparative Analysis by Unknown Stage Development, H1 2014 16
Products under Development by Companies, H1 2014 17
Products under Investigation by Universities/Institutes, H1 2014 18
Hairy Cell Leukemia - Pipeline by MedImmune, LLC, H1 2014 19
Hairy Cell Leukemia - Pipeline by Plexxikon Inc., H1 2014 20
Hairy Cell Leukemia - Pipeline by Incyte Corporation, H1 2014 21
Hairy Cell Leukemia - Pipeline by Mundipharma International Limited, H1 2014 22
Hairy Cell Leukemia - Pipeline by Onconova Therapeutics, Inc., H1 2014 24
Hairy Cell Leukemia - Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2014 25
Assessment by Monotherapy Products, H1 2014 26
Number of Products by Stage and Target, H1 2014 28
Number of Products by Stage and Mechanism of Action, H1 2014 30
Number of Products by Stage and Route of Administration, H1 2014 32
Number of Products by Stage and Molecule Type, H1 2014 34
Hairy Cell Leukemia Therapeutics - Recent Pipeline Updates, H1 2014 54
Hairy Cell Leukemia - Discontinued Products, H1 2014 67

List of Chart


Number of Products under Development for Hairy Cell Leukemia, H1 2014 8
Number of Products under Development for Hairy Cell Leukemia - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 10
Comparative Analysis by Clinical Stage Development, H1 2014 14
Assessment by Monotherapy Products, H1 2014 26
Number of Products by Top 10 Target, H1 2014 27
Number of Products by Stage and Top 10 Target, H1 2014 28
Number of Products by Top 10 Mechanism of Action, H1 2014 29
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 30
Number of Products by Top 10 Route of Administration, H1 2014 31
Number of Products by Stage and Top 10 Route of Administration, H1 2014 32
Number of Products by Top 10 Molecule Type, H1 2014 33
Number of Products by Stage and Top 10 Molecule Type, H1 2014 34

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *